IP Library Granted Patent US 9,302,012
Granted Patent B2
US 9,302,012 · App. 13/865,801 · Granted Apr 5, 2016

Anti-bacterial siderophore-aminopenicillin conjugates

Inventors: Marvin J. Miller (South Bend, IN); Cheng Ji (New York, NY); Patricia A. Miller (South Bend, IN)
Assignee: UNIVERSITY OF NOTRE DAME DU LAC
A61K47/48023A61K31/167A61K31/235A61K47/48076
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,302,012
App. No.
13/865,801
Granted
Apr 5, 2016
Kind
B2
Abstract

An artificial tris-catecolate siderophore with a tripodal backbone and its conjugates with ampicillin and amoxicillin were synthesized. Both conjugates exhibited significantly enhanced in vitro antibacterial activities against Gram-negative species compared to the parent drugs, especially against P. aeruginosa . The conjugates appear to be assimilated by an induced bacterial iron transport process as their activities were inversely related to iron concentration. The easily synthesized tris-catecolate siderophores can be used with a variety of drugs as conjugates to target antibiotic-resistant Gram-negative bacteria.

Claims (16)

1. A compound of Formula (I):

wherein

m is 0 or 1-11;

each R 1 is independently H, —C(═O)alkyl, —C(═O)aryl, or —C(═O)O-alkyl;

each R 2 is independently H, alkyl, alkoxy, hydroxy, carboxy, halo, nitro, amino, or cyano;

each n is independently 1, 2, or 3; and

X is amikacin, amoxicillin, ampicillin, amphotericin, aztreonam, bacillomycin, BAL30072, biapenem, carumonam, cefaclor, cefalotin, chloramphenicol, chlortetracycline, ciprofloxacin, clindamycin, clindamycin phosphate, cycloserine, daptomycin, demeclocycline, doripenem, doxorubicin, doxycycline, ertapeneme, erythromycin, ethambutol, erythromycin, gentamicin, imipenem, isoniazid, kanamycin, lincomycin, loracarbef, meropenem, methacycline, mupirocin, neomycin, nystatin, oxytetracycline, panipenem, pyrrolnitrin, rifampin, rolitetracycline, streptomycin, sulfacetamide, sulfabenzamide, sulfadiazine, sulfadoxine, sulfamerazine, sulfamethazine, sulfamethizole, sulfamethoxazole, sulfisoxazole, tetracycline, or tigimonam, X being covalently linked via an ester or amide bond;

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1 wherein each R 1 is acetyl, propanoyl, or benzoyl.

3. The compound of claim 1 wherein each R 2 is H, alkyl, alkoxy, or hydroxy.

4. The compound of claim 1 wherein each R 2 is H.

5. The compound of claim 1 wherein each n is 1.

6. The compound of claim 1 wherein m is 0, 1, 2, or 3.

7. The compound of claim 1 wherein X is ampicillin or amoxicillin.

8. The compound of claim 1 wherein the compound is

9. A composition comprising a compound of claim 1 and a pharmaceutically acceptable diluent or carrier.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 8, 2017
From: UNIVERSITY OF NOTRE DAME
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041494/0588 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2016
From: MILLER, MARVIN J.; JI, CHENG; MILLER, PATRICIA A.
To: UNIVERSITY OF NOTRE DAME DU LAC
Reel/Frame 037431/0643 →
Continuity (2)
Provisional Application 61687101 · Apr 18, 2012
Related Publication 20130281424A1 · Oct 24, 2013